Baseline Clinical and Laboratory Predictors of Treatment Requirement in Chronic Lymphocytic Leukemia: A Retrospective Cohort Study Using Hierarchical Modeling
Open Access
- 26 June 2026
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 16 (13) , 2003
Abstract
Background/Objectives: Chronic lymphocytic leukemia (CLL) is characterized by a highly heterogeneous clinical course, with some patients remaining stable for years while others require early treatment. Identifying reliable and easily accessible predictors of treatment requirement at diagnosis remains an important clinical challenge. Methods: This retrospective cohort study included 226 patients diagnosed with CLL between 2015 and 2024 at a tertiary care center. Baseline demographic, clinical, and laboratory parameters were analyzed. Univariate and multivariable logistic regression analyses were performed to identify independent predictors of treatment requirement. A hierarchical mixed-effects model was constructed to account for temporal clustering across diagnostic periods. A clinical risk score was derived from independent predictors, using regression coefficient-based weighting, and its discriminative performance was evaluated using receiver operating characteristic (ROC) analysis. Results: A total of 226 patients were included (mean age: 62.4 ± 13.8 years; 56.6% male). During follow-up, 104 patients (46.0%) required treatment. Lower hemoglobin and platelet levels, higher lymphocyte counts and LDH levels, and the presence of B symptoms, splenomegaly, and advanced disease stage were independently associated with treatment requirement. These associations remained significant in hierarchical modeling. The derived risk score demonstrated acceptable discriminative ability (AUC: 0.84; 95% CI: 0.79–0.89), with a cut-off value of ≥4 yielding a sensitivity of 81.7% and specificity of 73.8%. Conclusions: Baseline clinical and laboratory parameters are associated with treatment requirement in CLL. A combination of readily available variables may support risk stratification at diagnosis. The proposed risk score may provide a practical adjunct to routine clinical assessment, particularly in settings where advanced molecular testing is not readily available; however, external validation in independent cohorts is required before clinical implementation.Keywords
This publication has 32 references indexed in Scilit:
- Incidentally Detected Splenomegaly and Risk of Hematologic Cancer and Liver DiseaseJAMA Oncology, 2026
- Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and TherapyAmerican Journal of Hematology, 2025
- Unusual complications in the management of chronic lymphocytic leukemiaAmerican Journal of Hematology, 2022
- Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic proceduresAmerican Journal of Hematology, 2021
- Intermediate and advanced topics in multilevel logistic regression analysisStatistics in Medicine, 2017
- A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic LeukemiaCurrent Hematologic Malignancy Reports, 2017
- Chronic lymphocytic leukaemiaNature Reviews Disease Primers, 2017
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient dataThe Lancet Oncology, 2016
- Evaluation of clinical staging in chronic lymphocytic leukemia- population-based studyLeukemia & Lymphoma, 2006
- Assessing prognosis in patients with chronic lymphocytic leukemia a quarter of a century after Rai and Binet staging systemsAnnals of Oncology, 2004